Survey of US Patients with Multiple Sclerosis: Comparison of the New Electronic Interferon Beta-1b Autoinjector (BETACONNECT™) With Mechanical Autoinjectors

Overview

Journal Neurol Ther

Publisher Springer

Specialty Neurology

Date 2016 Jun 10

PMID 27277705

Citations 11

Authors

Donald A Barone

Barry A Singer

Lubo Merkov

Mark Rametta

Gustavo Suarez

Affiliations

Soon will be listed here.

Abstract

Introduction: Patients with multiple sclerosis (MS) generally undergo long-term treatment with disease-modifying therapies (DMTs). In the US, patients taking glatiramer acetate, interferon beta-1a, or interferon beta-1b, typically use a mechanical autoinjector. Recent survey results have shown that using an electronic autoinjector, such as BETACONNECT™ (Bayer Pharma AG) for interferon beta-1b/Betaseron (Bayer Pharma AG) may reduce injection discomfort and increase patient satisfaction with treatment. The aim of the current survey was to assess patient perceptions of BETACONNECT compared with mechanical autoinjectors using a survey integrated with demonstrations and simulated injections with BETACONNECT.

Methods: Patients with MS currently using mechanical autoinjectors for glatiramer acetate/Copaxone (Teva Pharmaceuticals USA, Inc.), interferon beta-1a/Rebif (EMD Serono Inc.), or interferon beta-1b/Extavia (Novartis Pharmaceuticals Corp.), participated in a 60-min in-person interview. Patients rated the importance of 18 ideal autoinjector attributes, and the performance of their current autoinjectors across these attributes. BETACONNECT was demonstrated and patients performed simulated injections with BETACONNECT before rating it across the same attributes. Patient overall autoinjector preference was assessed.

Results: Ninety patients completed the survey: 63 were using autoinjectors for Copaxone, 25 for Rebif, and 2 for Extavia. BETACONNECT scored higher than mechanical autoinjectors across all 18 attributes. The top attributes of an ideal autoinjector were the injection process is easy overall, easy to push the button to start the injection, and autoinjector is comfortable to hold during injections. Unique BETACONNECT features most valued by patients were the built-in dwell time, self-check function, greater ability to customize injections, adjustment of injection speed, low injection noise, and automatic needle retraction. Overall, 75 out of 90 patients (83%) expressed a preference for BETACONNECT over their current autoinjector.

Conclusion: BETACONNECT attributes and features were highly rated by patients, compared with both an ideal autoinjector and their current mechanical autoinjectors. These findings suggest that the use of BETACONNECT may increase patient satisfaction and potentially increase overall medication adherence.

Funding: Bayer HealthCare Pharmaceuticals.

Citing Articles

Autoinjectors for Administering Glatiramer Acetate in Relapsing Remitting Multiple Sclerosis in Europe: A Survey of Patient and Nurse Preferences.

Shirol S, Saboor R, Muller T Degener Neurol Neuromuscul Dis. 2024; 14:131-141.

PMID: 39723344 PMC: 11669291. DOI: 10.2147/DNND.S484306.

Quantifying Patient Capabilities and Setting the Stage for Future Development: Insights from a Sensor-Augmented Simulated Use Study with Pen Injectors.

Lange J, Schneider A, Jordi C Med Devices (Auckl). 2024; 17:271-283.

PMID: 39099757 PMC: 11298175. DOI: 10.2147/MDER.S478141.

The Adherence and Outcomes Benefits of Using a Connected, Reusable Auto-Injector for Self-Injecting Biologics: A Narrative Review.

Antalfy A, Berman K, Everitt C, Alten R, Latymer M, Godfrey C Adv Ther. 2023; 40(11):4758-4776.

PMID: 37733212 PMC: 10567963. DOI: 10.1007/s12325-023-02671-2.

Patient-based benefit-risk assessment of medicines: development, refinement, and validation of a content search strategy to retrieve relevant studies.

El Masri H, McGuire T, Dalais C, van Driel M, Benham H, Hollingworth S J Med Libr Assoc. 2022; 110(2):185-204.

PMID: 35440905 PMC: 9014953. DOI: 10.5195/jmla.2022.1306.

Autoinjector - A smart device for emergency cum personal therapy.

Roy A, Geetha R, Magesh A, Vijayaraghavan R, Ravichandran V Saudi Pharm J. 2021; 29(10):1205-1215.

PMID: 34703373 PMC: 8523323. DOI: 10.1016/j.jsps.2021.09.004.

References

Gold R, Wolinsky J, Amato M, Comi G . Evolving expectations around early management of multiple sclerosis. Ther Adv Neurol Disord. 2010; 3(6):351-67. PMC: 3002639. DOI: 10.1177/1756285610385608. View

Pozzilli C, Schweikert B, Ecari U, Oentrich W . Supportive strategies to improve adherence to IFN β-1b in multiple sclerosis--results of the βPlus observational cohort study. J Neurol Sci. 2011; 307(1-2):120-6. DOI: 10.1016/j.jns.2011.04.026. View

Treadaway K, Cutter G, Salter A, Lynch S, Simsarian J, Corboy J . Factors that influence adherence with disease-modifying therapy in MS. J Neurol. 2009; 256(4):568-76. DOI: 10.1007/s00415-009-0096-y. View

Compston A, Coles A . Multiple sclerosis. Lancet. 2008; 372(9648):1502-17. DOI: 10.1016/S0140-6736(08)61620-7. View

Lugaresi A . Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation?. Expert Opin Drug Deliv. 2009; 6(9):995-1002. DOI: 10.1517/17425240903134769. View

Tan H, Cai Q, Agarwal S, Stephenson J, Kamat S . Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Adv Ther. 2010; 28(1):51-61. DOI: 10.1007/s12325-010-0093-7. View

Ziemssen T, Sylvester L, Rametta M, Ross A . Patient Satisfaction with the New Interferon Beta-1b Autoinjector (BETACONNECT™). Neurol Ther. 2015; 4(2):125-36. PMC: 4685867. DOI: 10.1007/s40120-015-0036-y. View

Weller I, Saake A, Schreiner T, Vogelreuter J, Petroff N . Patient satisfaction with the BETACONNECT™ autoinjector for interferon beta-1b. Patient Prefer Adherence. 2015; 9:951-9. PMC: 4501165. DOI: 10.2147/PPA.S85917. View

Brennan P, Strombom I . Improving health care by understanding patient preferences: the role of computer technology. J Am Med Inform Assoc. 1998; 5(3):257-62. PMC: 61299. DOI: 10.1136/jamia.1998.0050257. View

10.

Ziemssen T, De Stefano N, Sormani M, Van Wijmeersch B, Wiendl H, Kieseier B . Optimizing therapy early in multiple sclerosis: An evidence-based view. Mult Scler Relat Disord. 2015; 4(5):460-469. DOI: 10.1016/j.msard.2015.07.007. View

11.

Kappos L, Polman C, Freedman M, Edan G, Hartung H, Miller D . Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006; 67(7):1242-9. DOI: 10.1212/01.wnl.0000237641.33768.8d. View

12.

Devonshire V, Lapierre Y, Macdonell R, Ramo-Tello C, Patti F, Fontoura P . The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol. 2010; 18(1):69-77. DOI: 10.1111/j.1468-1331.2010.03110.x. View

13.

Lugaresi A, Rottoli M, Patti F . Fostering adherence to injectable disease-modifying therapies in multiple sclerosis. Expert Rev Neurother. 2014; 14(9):1029-42. DOI: 10.1586/14737175.2014.945523. View

14.

Bayas A, Ouallet J, Kallmann B, Hupperts R, Fulda U, Marhardt K . Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study. Expert Opin Drug Deliv. 2015; 12(8):1239-50. DOI: 10.1517/17425247.2015.1057567. View

15.

di Cantogno E, Russell S, Snow T . Understanding and meeting injection device needs in multiple sclerosis: a survey of patient attitudes and practices. Patient Prefer Adherence. 2011; 5:173-80. PMC: 3090378. DOI: 10.2147/PPA.S14903. View

16.

Cohen B, Coyle P, Leist T, Oleen-Burkey M, Schwartz M, Zwibel H . Therapy Optimization in Multiple Sclerosis: a cohort study of therapy adherence and risk of relapse. Mult Scler Relat Disord. 2015; 4(1):75-82. DOI: 10.1016/j.msard.2014.09.214. View

17.

Singer B, Wray S, Miller T, Cascione M, Gupta A, Pardo G . Patient-rated ease of use and functional reliability of an electronic autoinjector for self-injection of subcutaneous interferon beta-1a for relapsing multiple sclerosis. Mult Scler Relat Disord. 2015; 1(2):87-94. DOI: 10.1016/j.msard.2011.11.002. View

18.

Brochet B, Lemaire G, Beddiaf A . [Reduction of injection site reactions in multiple sclerosis (MS) patients newly started on interferon beta 1b therapy with two different devices]. Rev Neurol (Paris). 2006; 162(6-7):735-40. DOI: 10.1016/s0035-3787(06)75071-8. View

19.

Bayas A . Improving adherence to injectable disease-modifying drugs in multiple sclerosis. Expert Opin Drug Deliv. 2013; 10(3):285-7. DOI: 10.1517/17425247.2013.763793. View